wiz/zbtb7a degrader bms-986470
Generic: WIZ/ZBTB7A Degrader BMS-986470
wiz/zbtb7a degrader bms-986470: 1 clinical trial tracked.
wiz/zbtb7a degrader bms-986470 evidence translation
What we can confirm
1 tracked trial
No verified listed developer
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about wiz/zbtb7a degrader bms-986470, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trials (1)
A Phase 1/2a, First-in-human, Randomized, Double-blinded, Placebo-controlled, Dose-finding Study in Healthy Volunteers and Participants With Sickle Cell Disease to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, pH and Food Effect, and Preliminary Efficacy of BMS-986470
Primary endpoint: Number of participants with adverse events (AEs)
InterventionalRandomizedquadruple224 targetStarted 2024-07Completion 2027-1132 sites · Canada, France, Italy, United Kingdom…Bristol-Myers Squibb